Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Sarepta licenses five LGMD gene therapy candidates from Myonexus; has option to buy company

Executive Summary

Sarepta Therapeutics Inc. licensed exclusive rights to five of Myonexus Therapeutics Inc.'s gene therapy pipeline programs in limb-girdle muscular dystrophies (LGMDs).
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Intra-Biotech Deal
    • Includes M&A Option

Related Companies

Advertisement
UsernamePublicRestriction

Register